Details of the Drug
General Information of Drug (ID: DM4MAZ1)
| Drug Name |
(4-chloro-1H-pyrazol-1-yl)(o-tolyl)methanone
|
||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
Pyrazole, 4-chloro-1-(2-methylbenzoyl)-; Cambridge id 5909430; TimTec1_002284; N-Benzoylpyrazole deriv., 21; AC1LB684; CHEMBL396796; ZINC37175; BDBM23713; CTK6H3704; LBFRMVGIANQWAQ-UHFFFAOYSA-N; MolPort-002-174-898; HMS1540H18; STK023958; AKOS000576907; MCULE-4587218544; 4-chloropyrazolyl 2-methylphenyl ketone; ST033210; 4-Chloro-1-(2-methylbenzoyl)-1H-pyrazole; 4-Chloro-1-(2-methylbenzoyl)-1H-pyrazole #; SR-01000524613; (4-chloropyrazol-1-yl)-(2-methylphenyl)methanone; SR-01000524613-1
|
||||||||||||||||||
| Indication |
|
||||||||||||||||||
| Drug Type |
Small molecular drug
|
||||||||||||||||||
| Structure |
![]() |
||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||
| #Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 220.65 | |||||||||||||||||
| Logarithm of the Partition Coefficient (xlogp) | 2.8 | ||||||||||||||||||
| Rotatable Bond Count (rotbonds) | 1 | ||||||||||||||||||
| Hydrogen Bond Donor Count (hbonddonor) | 0 | ||||||||||||||||||
| Hydrogen Bond Acceptor Count (hbondacc) | 2 | ||||||||||||||||||
| Chemical Identifiers |
|
||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||
| Drug-Molecule Activity Atlas (DMA)NEW | Click to Jump to the Detailed DMA Information of This Drug | ||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Discovery agent | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | N.A. | |||||||||||||||||
|
||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||


